Overview

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Status:
Recruiting

Trial end date:
2025-07-25

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Semaglutide